Anticoagulants vs Antiplatelet Drugs: A Comparison Chart for NP Students
By Roupen Odabashian, MD, FRCPC · Published · 10 min read
How we write and check articles: Editorial Policy.

Disclosure: Alma publishes this article and makes one of the study tools it discusses.
Short answer: anticoagulants slow the clotting cascade (warfarin cuts the making of clotting factors; heparin and its relatives, and the oral "-xaban" and "-gatran" drugs, block factors Xa or thrombin). Antiplatelet drugs stop platelets from activating and sticking together (aspirin blocks cyclooxygenase; clopidogrel, prasugrel and ticagrelor block the platelet P2Y12 receptor). In the labels, anticoagulant indications cluster around venous thromboembolism and atrial fibrillation, and antiplatelet indications cluster around acute coronary syndrome, recent myocardial infarction, stroke and peripheral artery disease. There are exceptions, which the chart shows.
This is exam study material for NP students, not clinical guidance. Every drug fact below comes from the FDA-approved label on DailyMed, opened on November 7, 2026, with the set ID and effective date in the Sources list. It gives no dosing instructions (the heparin row quotes the label's protamine neutralization ratio). Labels are revised, so read the current one before you prescribe.
How do the two classes differ at a glance?
| Anticoagulants | Antiplatelet drugs | |
|---|---|---|
| Target | Clotting factors or their synthesis | Platelet activation and aggregation |
| Examples read here | Warfarin, heparin, enoxaparin, apixaban, rivaroxaban, dabigatran | Aspirin (in a combination label), clopidogrel, prasugrel, ticagrelor |
| Typical label indications | Venous thrombosis and pulmonary embolism, stroke prevention in atrial fibrillation, prophylaxis after hip or knee replacement | Acute coronary syndrome, recent MI or stroke, peripheral artery disease, stroke or TIA |
| Lab test the label ties to dosing | INR (warfarin), aPTT (heparin) | Not covered on this page |
| Shared worry | Bleeding | Bleeding |
Anticoagulants: the chart
| Drug (label read) | Mechanism as the label states it | Indications (selected) | Boxed warning | Reversal, as the label states it |
|---|---|---|---|---|
| Warfarin (Jantoven label)[1] | Inhibits synthesis of vitamin K-dependent clotting factors II, VII, IX and X and the anticoagulant proteins C and S, by inhibiting VKORC1 | Prophylaxis and treatment of venous thrombosis and PE; thromboembolic complications of atrial fibrillation and cardiac valve replacement; reducing death, recurrent MI and thromboembolic events after MI | Bleeding risk: major or fatal bleeding; regular INR monitoring | Stop the drug and, if necessary, give vitamin K1; PCC, fresh frozen plasma or activated factor VII may be considered if reversal is urgent |
| Heparin (unfractionated)[2] | Binds antithrombin III and enhances its inhibition of activated factors, particularly Xa and IIa; small amounts inhibit Xa, larger amounts inhibit thrombin; does not lyse existing clots | Prophylaxis and treatment of venous thrombosis and PE; atrial fibrillation with embolization; DIC; arterial and cardiac surgery; extracorporeal circulation and dialysis | None in the label read; HIT is a warning (5.3) | Protamine sulfate neutralizes heparin; each mg neutralizes about 100 USP units, and less is needed as time passes |
| Enoxaparin (Lovenox)[3] | Low molecular weight heparin; label reports a higher anti-factor Xa to anti-factor IIa ratio than heparin (14.0 versus 1.22) | DVT prophylaxis (abdominal, hip, knee surgery, medical patients); treatment of acute DVT; unstable angina and non-Q-wave MI with aspirin; STEMI with aspirin | Spinal or epidural hematomas | Protamine can largely neutralize it, but anti-factor Xa activity is never completely neutralized (maximum about 60%) |
| Apixaban (Eliquis)[4] | Selective inhibitor of factor Xa; does not need antithrombin III; no direct effect on platelet aggregation | Stroke and systemic embolism in nonvalvular AF; DVT prophylaxis after hip or knee replacement; treatment of DVT and PE; reducing recurrence | (A) Premature discontinuation increases thrombotic events; (B) spinal or epidural hematoma | Label says a specific reversal agent (andexanet alfa) is available for adults; PCC may be considered; protamine and vitamin K are not expected to affect it |
| Rivaroxaban (Xarelto)[5] | Selective inhibitor of factor Xa; needs no cofactor such as antithrombin III | Stroke and systemic embolism in nonvalvular AF; DVT and PE treatment and recurrence; prophylaxis; with aspirin in CAD and PAD | Same two as apixaban | Overdosage section: "A specific agent to reverse the anti-factor Xa activity of rivaroxaban is not available"; PCC, activated PCC or recombinant factor VIIa may be considered but have not been evaluated in clinical efficacy and safety studies; protamine and vitamin K are not expected to affect it |
| Dabigatran (Pradaxa)[6] | Competitive, direct thrombin inhibitor | Stroke and systemic embolism in non-valvular AF; DVT and PE treatment and recurrence; prophylaxis after hip replacement | Same two as apixaban | Label directs use of a specific reversal agent, idarucizumab, for emergency surgery or urgent procedures when reversal is needed in adults |
Two points to hold onto from the chart. First, the apixaban and rivaroxaban labels differ on whether a specific reversal agent is available. Both were read on the same day, and product availability can change, so on an exam follow the stem and your reference and not this table alone. Second, dabigatran's label contraindicates it in all patients with a mechanical prosthetic valve, based on the RE-ALIGN trial, where it caused more thromboembolic and major bleeding events than warfarin[6].
Antiplatelet drugs: the chart
| Drug (label read) | Mechanism as the label states it | Indications (selected) | Warning highlights |
|---|---|---|---|
| Aspirin (in the aspirin and extended-release dipyridamole label)[7] | Irreversible inhibition of platelet cyclooxygenase, which inhibits thromboxane A2 generation; dipyridamole adds an adenosine-uptake effect | The combination reduces the risk of stroke in patients who have had TIA or a completed ischemic stroke due to thrombosis | We did not read a single-ingredient aspirin label for this page |
| Clopidogrel (Plavix)[8] | Irreversible binding of its active metabolite to the P2Y12 ADP receptor | ACS (with aspirin); recent MI, recent stroke or established peripheral arterial disease | Boxed: diminished antiplatelet effect in patients with two loss-of-function CYP2C19 alleles (poor metabolizers); consider another P2Y12 inhibitor |
| Prasugrel (Effient)[9] | Irreversible binding of its active metabolite to the P2Y12 receptor | ACS managed with PCI | Boxed: bleeding; contraindicated with prior TIA or stroke; generally not recommended at 75 or older; do not start if urgent CABG is likely |
| Ticagrelor (Brilinta)[10] | Reversibly interacts with the platelet P2Y12 ADP receptor | ACS or history of MI; CAD at high risk; acute ischemic stroke or high-risk TIA | Boxed: bleeding; do not use with active pathological bleeding or prior intracranial hemorrhage; if possible manage bleeding without stopping, because stopping raises the risk of cardiovascular events |
What do the boxed warnings have in common?
- All three oral anticoagulants and enoxaparin carry a boxed warning for spinal or epidural hematoma, and the risk factors the labels list include indwelling epidural catheters and concomitant NSAIDs, platelet inhibitors and other anticoagulants[3][4][5][6].
- All three oral anticoagulants warn that stopping early, for a reason other than bleeding or finishing a course, raises the risk of thrombotic events[4][5][6]. Ticagrelor's label makes a parallel point for antiplatelet therapy[10].
- Combining the two classes raises bleeding risk: the dabigatran label lists antiplatelet agents, heparin, fibrinolytics and chronic NSAID use as bleeding risk factors[6].
A memory scaffold (ours, not from the labels)
We wrote these two hooks ourselves. They are study patterns, not text from any label.
- Name endings. The anticoagulants apixaban and rivaroxaban end in "-xaban" and block factor Xa; dabigatran ends in "-gatran" and blocks thrombin (factor IIa)[4][5][6]. Clopidogrel, prasugrel and ticagrelor all have "-grel" in the name and block P2Y12[8][9][10].
- Warfarin factors. Warfarin lowers factors 2, 7, 9 and 10, plus proteins C and S[1].
Five practice questions
Exam study material, not clinical guidance. The items are original, and each answer is keyed to the labels cited.
1. Which drug enhances antithrombin III activity, whereas apixaban does not need antithrombin III? A. Warfarin B. Heparin C. Clopidogrel D. Dabigatran
2. Warfarin lowers the activity of which set of clotting factors? A. I, V, VIII, XII B. II, VII, IX, X C. III, IV, XI, XIII D. VIII, IX, XI only
3. Which of these P2Y12 inhibitors binds reversibly? A. Clopidogrel B. Prasugrel C. Ticagrelor D. Aspirin
4. Which specific reversal agent does the dabigatran label name? A. Protamine sulfate B. Vitamin K1 C. Idarucizumab D. Activated charcoal only
5. Which laboratory test does each label tie to dosing: warfarin and heparin respectively? A. aPTT and INR B. INR and aPTT C. INR and INR D. Platelet count and INR
Answers and rationales
- B. Heparin works through antithrombin III[2]. Apixaban does not require it[4].
- B. Factors II, VII, IX and X, plus proteins C and S[1].
- C. Ticagrelor reversibly interacts with the P2Y12 receptor, while clopidogrel and prasugrel bind irreversibly through active metabolites[8][9][10]. Aspirin is not a P2Y12 inhibitor; it inhibits cyclooxygenase[7].
- C. The dabigatran label directs a specific reversal agent, idarucizumab[6], whose own label describes it as a Fab fragment that binds dabigatran[11].
- B. Warfarin dosing follows the INR[1]; heparin dosage is adjusted to coagulation tests, with adequacy defined by aPTT[2].
How can you study this with Alma?
Alma's flashcards use the FSRS spaced-repetition scheduler. You can make a card per drug from your own notes, and add an AI picture to a card, including a cartoon-mnemonic style, that you preview and keep only if it is right. Check any picture against the label text, because an AI picture can get a clinical detail wrong. Rows in the charts above are good card fronts: "Ticagrelor: reversible or irreversible?" See Alma flashcards and Alma's mnemonic generator. For the wider NP picture see the NP hub.
Frequently asked questions
What is the main difference between an anticoagulant and an antiplatelet drug? Anticoagulants act on clotting factors or their synthesis; antiplatelet drugs act on platelet activation. The mechanism rows in the charts show each drug's exact target[1][2][4][8].
Is aspirin an anticoagulant? No. In the label we read, aspirin inhibits platelet aggregation through irreversible inhibition of platelet cyclooxygenase[7].
Which anticoagulants are monitored by lab tests? Warfarin dosing follows the INR and heparin dosing follows coagulation tests such as aPTT[1][2].
Can both classes be given together? Some labels list indications "in combination with aspirin", for example enoxaparin and rivaroxaban[3][5]. The labels also warn that combining drugs that affect hemostasis raises bleeding risk[3][4][5][6]. This page does not give advice for any patient.
Sources
Opened on DailyMed on November 7, 2026. Each entry gives the set ID and effective date of the label version read. Labels are revised, so check the current version.
- Jantoven (warfarin sodium) tablets, Upsher-Smith Laboratories, set ID 19a69a72-ac5d-45d5-a94d-a5aaecbe4730, effective October 28, 2026: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=19a69a72-ac5d-45d5-a94d-a5aaecbe4730
- Heparin sodium injection, Hospira, Inc., set ID c8c4edd2-ee9e-4558-6b8c-b83adc242a0a, effective August 25, 2026: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c8c4edd2-ee9e-4558-6b8c-b83adc242a0a
- Lovenox (enoxaparin sodium) injection, Sanofi-Aventis U.S. LLC, set ID 5017a927-2a24-4f27-89f9-27c805bf7d59, effective May 28, 2026: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5017a927-2a24-4f27-89f9-27c805bf7d59
- Eliquis (apixaban) tablets, E.R. Squibb and Sons, set ID e9481622-7cc6-418a-acb6-c5450daae9b0, effective April 17, 2025: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e9481622-7cc6-418a-acb6-c5450daae9b0
- Xarelto (rivaroxaban) tablets, Janssen Pharmaceuticals, Inc., set ID 10db92f9-2300-4a80-836b-673e1ae91610, effective September 10, 2026: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610
- Pradaxa (dabigatran etexilate) capsules, Boehringer Ingelheim Pharmaceuticals, set ID ba74e3cd-b06f-4145-b284-5fd6b84ff3c9, effective June 25, 2025: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9
- Aspirin and extended-release dipyridamole capsules, AvKARE, set ID c9a73ec9-e468-46a5-b2c1-99f1f1536585, effective January 14, 2026: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c9a73ec9-e468-46a5-b2c1-99f1f1536585
- Plavix (clopidogrel) tablets, Sanofi-Aventis U.S. LLC, set ID de8b0b67-eb25-4684-83b5-7ad785314227, effective May 30, 2025: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=de8b0b67-eb25-4684-83b5-7ad785314227
- Effient (prasugrel) tablets, Cosette Pharmaceuticals, set ID 69ea2d58-5353-4222-b61f-cab976fa7e5e, effective September 7, 2022: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=69ea2d58-5353-4222-b61f-cab976fa7e5e
- Brilinta (ticagrelor) tablets, AstraZeneca Pharmaceuticals LP, set ID f7b3f443-e83d-4bf2-0e96-023448fed9a8, effective May 7, 2026: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f7b3f443-e83d-4bf2-0e96-023448fed9a8
- Praxbind (idarucizumab) injection, Boehringer Ingelheim Pharmaceuticals, set ID c7400f8a-dcf4-a6df-6d07-983081b1bf34, effective January 23, 2024: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c7400f8a-dcf4-a6df-6d07-983081b1bf34